AndreaBozzo/ceres-open-data-index huggingface dataset:
Apical accumulation of MARCKS in neural plate cells during neurulation in the chick embryo

Background
          The neural tube is formed by morphogenetic movements largely dependent on cytoskeletal dynamics. Actin and many of its associated proteins have been proposed as important mediators of neurulation. For instance, mice deficient in MARCKS, an actin cross-linking membrane-associated protein that is regulated by PKC and other kinases, present severe developmental defects, including failure of cranial neural tube closure.
        
        
          Results
          To determine the distribution of MARCKS, and its possible relationships with actin during neurulation, chick embryos were transversely sectioned and double labeled with an anti-MARCKS polyclonal antibody and phalloidin. In the neural plate, MARCKS was found ubiquitously distributed at the periphery of the cells, being conspicuously accumulated in the apical cell region, in close proximity to the apical actin meshwork. This asymmetric distribution was particularly noticeable during the bending process. After the closure of the neural tube, the apically accumulated MARCKS disappeared, and this cell region became analogous to the other peripheral cell zones in its MARCKS content. Actin did not display analogous variations, remaining highly concentrated at the cell subapical territory. The transient apical accumulation of MARCKS was found throughout the neural tube axis. The analysis of another epithelial bending movement, during the formation of the lens vesicle, revealed an identical phenomenon.
        
        
          Conclusions
          MARCKS is transiently accumulated at the apical region of neural plate and lens placode cells during processes of bending. This asymmetric subcellular distribution of MARCKS starts before the onset of neural plate bending. These results suggest possible upstream regulatory actions of MARCKS on some functions of the actin subapical meshwork.
Breast cancer mortality among Ashkenazi Jewish women in São Paulo and Porto Alegre, Brazil

Background
          Increased BRCA1 and BRCA2 germline mutation rates have been reported in Ashkenazi Jewish women in North America, Europe and Israel, and have been mentioned as possibly related to a higher incidence of breast and ovarian cancer among these communities. The present study was carried out with the aim of obtaining evidence on the magnitude of breast cancer as a cause of death among Ashkenazi women in Brazil.
        
        
          Methods
          We reviewed all death certificates archived in the Jewish Burial Societies of São Paulo (1971-1997) and Porto Alegre (1948-1997), two of the main and oldest Jewish communities in Brazil. Breast cancer observed deaths were compared with expected deaths according to breast cancer mortality in the general population.
        
        
          Results
          The observed ratios were approximately quite close to unity, suggesting a similar breast cancer mortality pattern among the Ashkenazi population and the general population in both cities. These results maintain similar behavior regardless of whether analyzed before or after the mid-1980s, when mammography came to be increasingly performed in Brazil. Cancer proportional mortality ratios were 1.04 (0.83-1.29) in São Paulo and 1.16 (0.84-1.57) in Porto Alegre before 1985, and 1.17 (1.00-1.44) and 1.21 (0.81-1.79), respectively, between 1985 and 1997. Some evidence of the maintenance of protective risk factors such as high parity has been observed among Ashkenazi women in São Paulo.
        
        
          Conclusion
          A quite similar breast cancer mortality pattern was observed between Ashkenazi Jewish women and the general population in São Paulo and Porto Alegre, Brazil. These results may suggest an environmental role on germ mutation expression reported in this ethnic group.
#DDOD Use Case: Accuracy of healthcare.gov Plan Finder

<p>SUMMARY</p>
<p>DDOD use case to verify the accuracy of data obtained from the HealthCare Finder API after a user identified potential data quality issues.</p>
<p>WHAT IS A USE CASE?</p>
<p>A “Use Case” is a request that was made by the user community because there were no available datasets that met their particular needs.  If this use case is similar to your needs, we ask that you add your own requirements to the specifications section.</p>
<p>The concept of a use case falls within the <a href="http://hhs.ddod.us ">Demand-Driven Open Data</a> (DDOD) program and gives you a formalized way to identify what data you need.  It’s for anyone in industry, research, media, nonprofits or other government agencies.  Each request becomes a DDOD use case, so that it can be prioritized and worked on.</p>
<p>Use Cases also provide a wealth of insights about existing alternative datasets and tips for interpreting and manipulating data for specific purposes.</p>
<p>PURPOSE</p>
<p>Clarity is needed around how completeness of the data via the HealthFinder API.</p>
<ul>
<li>Is it intended to be a complete data set?  e.g., does it have every on- and off-exchange plan available in the country? </li>
<li> If it is not intended to be a complete data set, what fields (eg, plans, issuers, scenarios) are systematically missing in the data?</li>
<li> Why are there specific cases of known plans that are missing in the data (eg, no Carefirst/BCBS plans in Virgina)?</li>
</ul>
<p>VALUE</p>
<p>In order for the HealthCare Finder API to be useful, it must be a trusted source and accurate; if there are data gaps, those must be clearly documented.  The API is critical in assisting the users to find the best healthcare plans.</p>
<p>USE CASE SPECIFICATIONS &amp; SOLUTION</p>
<p>Information about this use cases is maintained in a wiki: <a href="http://hhs.ddod.us/wiki/Use_Case_28:_Verify_accuracy_of_healthcare.gov_Plan_Finder">http://hhs.ddod.us/wiki/Use_Case_28:_Verify_accuracy_of_healthcare.gov_P...</a></p>
<p>It serves as a knowledge base.</p>
<p>USE CASE DISCUSSION FORUM</p>
<p>All communications between Data Users, DDOD Administrators and Data Owners are logged as discussions within GitHub issues: <a href="https://github.com/demand-driven-open-data/ddod-intake/issues/28">https://github.com/demand-driven-open-data/ddod-intake/issues/28</a></p>
<p>It aims to provide complete transparency into the process and ensure the same message gets to all participants.</p>
<p>CASE STATUS</p>
<p>Closed. PlanFinder is intended for off-exchange (off FFM) plans only. PlanFinder is not meant to be a comprehensive list of every plan available; it is only intended to display the potential options for consumers looking to purchase insurance off the exchange.  While there is some overlap where many on-exchange plans appear in the dataset, this  does not guarantee a comprehensive list of every plan.</p>
<p>The PlanFinder API and website return the same data.</p>
<p>On-exchange plans are also available on data.healthcare.gov under the term "QHP" (Qualified Health Plan).</p>
Patent AT-E401703-T1: [Translated] IMPLEMENTATION OF A TRANSFORMATION AND A FOLLOWING QUANTIZATION

The invention relates to an approximation of a DCT and a quantization which are to be applied subsequently to digital data for compression of this digital data. In order to improve the transform, it is proposed to simplify a predetermined transform matrix to require less operations when applied to digital data. In addition, elements of the simplified transform matrix constituting irrational numbers are approximated by rational numbers. These measures are compensated by extending a predetermined quantization to compensate for the approximation of elements of the simplified transform matrix by rational numbers. If the simplified transform matrix and the extended quantization are used as basis for implementation, a fast transform with a good resulting quality can be achieved. An approximation of an IDCT employed in decompression of compressed digital data can be simplified correspondingly.
Building Strong Families (BSF)

The Building Strong Families (BSF) project examined the effectiveness of programs designed to improve child well-being and strengthen the relationships of low-income couples through relationship skills education. It surveyed couples 15 months and 36 months after having applied to and been accepted into a Building Stronger Families (BSF) program at one of eight locations offering services to unwed couples expecting, or having recently had a baby. Major topics included family structure, parental involvement with children, relationships, personal and parental well-being, utilization of services such as workshops to help their relationship and parenting skills, paternity and child support, and family self-sufficiency. Respondents were asked for information on recently born children and relationship status, how much time they spent with their children, their level of satisfaction with their current relationship, substance use, if they had attended relationship and parental counseling, whether they were legally required to provide child support, employment, and family background. Additional information was asked about domestic violence and child abuse, legal trouble, past sexual history, and child development. The 36-month data collection effort also included direct assessments of parenting and child development. The quality of the parenting relationship was assessed for both mothers and fathers and was based on a semi-structured play activity, "the two-bag task." This interaction was videotaped and later coded by trained assessors on multiple dimensions of parenting. During assessments with mothers, the focal child's language development was also assessed using the Peabody Picture Vocabulary Test. Demographic data includes race, education level, age, income, and marital status. The data collection is comprised of seven parts. Part 1: the BSF Eligibility and Baseline Survey Data file; Part 2: the BSF 15-Month Follow-up Survey Data file; Part 3: the program participation data file; Part 4: the BSF 15-month follow-up analysis file; Part 5: the BSF 36-Month Follow-up Survey Data file; Part 6: the mother-child in-home assessment; and Part 7: the BSF 36-Month Follow-up analysis file.

<b>Units of Response: </b>Low-income couples with children

<b>Type of Data: </b>Evaluation

<b>Tribal Data: </b>No

<b>COVID-19 Data: </b>No

<b>Periodicity: </b>One-time

<b>SORN: </b>https://www.federalregister.gov/documents/2022/09/19/2022-20139/privacy-act-of-1974-system-of-records

<b>Data Use Agreement: </b>https://www.icpsr.umich.edu/rpxlogin

<b>Data Use Agreement Location: </b>https://www.icpsr.umich.edu/web/ICPSR/studies/29781/datadocumentation

<b>Equity Indicators: </b>Sex 

<b>Granularity: </b>Household;Individual

<b>Spatial: </b>United States

<b>Geocoding: </b>Unavailable
Compound 526984: 3-Cedrene

Chemical compound data from PubChem database. IUPAC Name: 2,6,6,8-tetramethyltricyclo[5.3.1.01,5]undec-3-ene. Molecular Formula: C15H24. Molecular Weight: 204.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400815-T1: [Translated] METHOD FOR ASSESSING THE CONSISTENCY OF MALIGNANT TUMORS

A method for judging feature of malignant tumor is described herein. The method comprises obtaining step, first comparing step, second comparing step, and judging step. The obtaining step comprises obtaining a first parameter based on activity and expression level of a first CDK contained in a tumor cell of the malignant tumor, a second parameter based on activity and expression level of a second CDK contained in the tumor cell, a third parameter based on the first parameter and the second parameter, and a fourth parameter based on expression level of a growth factor receptor in the tumor cell. The first comparing step comprises comparing a first threshold value with the third parameter. The second comparing step comprises comparing a second threshold value with the fourth parameter. The judging step comprises judging the feature based on the comparison results of the first comparing step and the second comparing step. Also described is a computer program or program product executing the steps of the method.
Child Abuse Prevention and Treatment Act (CAPTA) State Grants

Program Description

The Child Abuse Prevention and Treatment Act (CAPTA) State Grant program provides grants to help states improve child protective service systems. This program assists states in improving: intake, assessment, screening and investigation of child abuse and neglect reports; risk and safety assessment protocols; training for child protective services workers and mandated reporters; programs and procedures for the identification, prevention and treatment of child abuse and neglect; development and implementation of procedures for collaboration among child protection services, domestic violence, and other agencies; and services to disabled infants with life-threatening conditions and their families. In addition, under this program, states perform a range of prevention activities, including addressing the needs of infants born with prenatal drug exposure, referring children not at risk of imminent harm to community services, implementing criminal record checks for prospective foster and adoptive parents and other adults in their homes, training child protective services workers, protecting the legal rights of families and alleged perpetrators, and supporting Citizen Review Panels.

Since FY 2018, Congress has directed that $60 million of the annual appropriation be used to help states improve their response to the families of infants affected by substance use disorders. States are required to use a substantial portion of their annual grant to strengthen procedures for the development, implementation and monitoring of plans of safe care for substance-exposed infants and their caretakers.

Budget Information

FY 2024: $105 million

Metadata-only record linking to the original dataset. Open original dataset below.
Debate: Should the elderly receive thrombolytic therapy, or primary angioplasty, for acute myocardial infarction? The case for primary angioplasty

As the population ages the number of elderly patients presenting with acute myocardial infarction (AMI) will continue to increase. There has been no head-to-head trial of thrombolytic therapy versus primary percutaneous coronary intervention (PCI) in this patient cohort, but there is evidence that favors primary PCI. Most elderly patients are candidates for primary PCI, but many have contraindications to thrombolytic therapy. Hemorrhagic complications are more common in the elderly, and many of these patients present with conditions in which thrombolytic agents have decreased efficacy, such as heart failure or prior bypass surgery. PCI can also obviate the need for further risk stratification in most patients.
Decitabine

Decitabine is a generic prescription drug used to treat certain blood cancers like myelodysplastic syndromes and acute myeloid leukemia. It comes as a lyophilized powder for intravenous injection, with each vial containing 50 mg of the active ingredient. Manufactured by Novadoz Pharmaceuticals LLC under ANDA 212265. This information was generated using AI and is provided for informational and research purposes only.
Compound 528185: 1,3-Cyclopentadiene, 5-hexyl

Chemical compound data from PubChem database. IUPAC Name: 5-hexylcyclopenta-1,3-diene. Molecular Formula: C11H18. Molecular Weight: 150.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Debate: The slippery slope of surrogate outcomes

Surrogate outcomes are frequently used in cardiovascular disease research. A concern is that changes in surrogate markers may not reflect changes in disease outcomes. Two recent clinical trials (Heart and Estrogen/Progestin Replacement Study [HERS], and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]) underscore this problem since their results contradicted what was expected based on the surrogate outcomes. The current regulatory policy to allow new therapies to be introduced onto the market based solely on surrogate outcomes may need to be reviewed.
2013 CMHS Uniform Reporting System (URS) Tables Alaska

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Alaska for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Travoprost (isomer free)

Travoprost (isomer free) is a prescription eye drop medication, a prostaglandin analog, used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It comes as a 0.004% ophthalmic solution in a 5 mL bottle, manufactured by Somerset Therapeutics, LLC. This information was generated using AI and is provided for informational and research purposes only.
2014 CMHS Uniform Reporting System (URS) Table for Puerto Rico

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Puerto Rico. The URS territories reporting system is collected annually to support the Community Mental Health Services Block Grant program. Territories Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Vision Service Plan (VSP) – Vision and Eye Health Surveillance

2016. This dataset is a de-identified summary table of vision and eye health data indicators from VSP, stratified by all available combinations of age group, race/ethnicity, gender, and state. VSP claims for VEHSS provides a convenience sample of vision insurance members representing approximately more than 1 in 4 of the U.S. population. VSP uses a web-based claims submissions system to collect and process claims. The denominator of the rates represents persons with VSP benefits as reported by employers, and is subject to some uncertainty.  VSP data for VEHSS include Service Utilization and Eye Health Condition indicators.  Certain ophthalmic conditions and procedures are covered by health insurance and are not covered by managed vision insurance, claims based eye disease prevalence may therefore be expected to undercount true prevalence.  Person level claims and person counts are not publically available.  Reported rates were suppressed for de-identification to ensure protection of patient privacy. Detailed information on VEHSS VSP analyses can be found on the VEHSS VSP webpage (link). Information on VSP data can be found on the VSP website (www.vsp.com). The VEHSS VSP dataset was last updated in June 2018.
Child Abuse Prevention and Enforcement Act, 2000

Title I: The Child Abuse Prevention and Enforcement Act - Child Abuse Prevention and Enforcement Act - Amends the Crime Identification Technology Act of 1998 to authorize the use of funds under the State grant program for criminal justice identification, information, and communication for programs to develop, update, or upgrade the capability of the criminal justice system to deliver timely, accurate, and complete criminal history record information to child welfare agencies, organizations, and programs that are engaged in the assessment of activities related to the protection of children, including protection against child sexual abuse and placement of children in foster care.

(Sec. 103) Amends the Omnibus Crime Control and Safe Streets Act of 1968 to allow the use of drug control and system improvement (Byrne) grants to be used: (1) to enforce child abuse and neglect laws, including laws protecting against child sexual abuse, and to promote programs designed to prevent child abuse and neglect; and (2) to establish or support cooperative programs between law enforcement and media organizations to collect, record, retain, and disseminate information useful in the identification and apprehension of suspected criminal offenders.

(Sec. 104) Amends the Victims of Crime Act of 1984 to provide for a conditional adjustment in the set aside for child abuse victims. Directs that such adjustment be implemented so that any increase in funding provided shall operate notwithstanding any dollar limitation on the availability of the Crime Victims Fund.

Title II: Jennifer's Law - Jennifer's Law - Authorizes the Attorney General to provide grant awards to enable States to improve the reporting of unidentified and missing persons. Authorizes appropriations.

Metadata-only record linking to the original dataset. Open original dataset below.
Honolulu, HI

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Honolulu, HI metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Honolulu metro area, Hawaii, and the U.S. overall.
Nevada Initiative to Reduce Long-Term Foster Care Permanency Innovations Initiative (PII) Grantee Profile

The Washoe County Department of Social Services aims to reduce the number of children in long-term foster care by implementing an intervention approach, SAFE-FC, to keep children safe, prevent them from coming into care, and to improve permanency outcomes for subgroups of children that have the most serious barriers to permanency.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401321-T1: [Translated] BETA-LACTAMES FOR THE TREATMENT OF CNS DISEASES

Chemical patent from PubChem database. Patent Number: AT-E401321-T1. Title: Crystalline Forms of Chemical Compounds. Filing Date: 2005-11-09. Inventors: Anderson, Robert, Davis, Linda. Abstract: The invention provides novel crystalline forms of chemical compounds, characterized by specific X-ray powder diffraction patterns and thermal properti... IPC Classifications: C12N, C12P, A61K. This patent covers 18 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 530349: N-methyl-2-phenyl-N-(1-phenyl-1-trimethylsilyloxypropan-2-yl)butanamide

Chemical compound data from PubChem database. IUPAC Name: N-methyl-2-phenyl-N-(1-phenyl-1-trimethylsilyloxypropan-2-yl)butanamide. Molecular Formula: C23H33NO2Si. Molecular Weight: 383.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401673-T1: [Translated] FUEL CELL SYSTEM AND METHOD FOR OPERATING SUCH SYSTEM

The system has an arrangement (1) for producing hydrogen with a reformer (2) and several gas cleaning stages (3). A gas burner (5) with an exhaust gas feed (4) heats the reformer. A polymer electrolyte membrane or PEM fuel cell (6) has connections (7, 8) for feeding in oxygen and the hydrogen produced by the arrangement. The exhaust gas feed of the gas burner is connected to the oxygen feed connection of the fuel cell. <??>AN Independent claim is also included for the following: a method of operating an inventive system.
Compound 525588: N,N-Dimethyl-N'-(4-bromophenyl)-p-methoxybenzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-bromophenyl)-4-methoxy-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C16H17BrN2O. Molecular Weight: 333.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.